Literature DB >> 20656218

Rupture of vulnerable atherosclerotic plaques: microRNAs conducting the orchestra?

Vincent G Haver1, Riemer H J A Slart, Clark J Zeebregts, Maikel P Peppelenbosch, René A Tio.   

Abstract

MicroRNAs (miRNAs) are tiny, endogenous nucleotides that bind to mRNA and induce translation repression within metazoan cells. Since their discovery in 1993 in Caenorhabditis elegans and the demonstration of miRNAs in Homo sapiens in 2000, research has been fruitful in deciphering the role of these nucleotides in development, tissue homeostasis, and pathologic processes. In humans, around 700 human miRNA nucleotides have been verified, which interfere with 30% of all genes. Recently, the role of miRNA in cardiovascular research gained attention and the involvement of miRNAs in several cardiovascular diseases has been identified. In this review, we focus on the role of miRNAs in atherosclerosis and in particular on the potential role of miRNAs in the development of vulnerable atherosclerotic plaques. The role of miRNA in the main characteristics of these plaques, inflammation, angiogenesis, and apoptosis will be discussed. Finally, the future perspectives and miRNA-based diagnostic and therapeutic potentials will be highlighted. Copyright (c) 2010 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20656218     DOI: 10.1016/j.tcm.2010.04.002

Source DB:  PubMed          Journal:  Trends Cardiovasc Med        ISSN: 1050-1738            Impact factor:   6.677


  13 in total

Review 1.  MicroRNA in ischemic stroke etiology and pathology.

Authors:  Cameron Rink; Savita Khanna
Journal:  Physiol Genomics       Date:  2010-09-14       Impact factor: 3.107

2.  Association between microRNAs and coronary collateral circulation: is there a new role for the small non-coding RNAs?

Authors:  Nikolaos Papageorgiou; Effimia Zacharia; Dimitris Tousoulis
Journal:  Ann Transl Med       Date:  2016-06

Review 3.  The plaque "micro" environment: microRNAs control the risk and the development of atherosclerosis.

Authors:  Katey J Rayner; Kathryn J Moore
Journal:  Curr Atheroscler Rep       Date:  2012-10       Impact factor: 5.113

4.  Intracellular and Extracellular miRNAs in Regulation of Angiogenesis Signaling.

Authors:  Nnenna A Finn; Charles D Searles
Journal:  Curr Angiogenes       Date:  2012-12

5.  Structural evidence of anti-atherogenic microRNAs.

Authors:  Anthony Virtue; Jietang Mai; Ying Yin; Shu Meng; Tran Tran; Xiaohua Jiang; Hong Wang; Xiao-Feng Yang
Journal:  Front Biosci (Landmark Ed)       Date:  2011-06-01

6.  MicroRNAs and other mechanisms regulate interleukin-17 cytokines and receptors.

Authors:  Jietang Mai; Anthony Virtue; Erin Maley; Tran Tran; Ying Yin; Shu Meng; Meghana Pansuria; Xiaohua Jiang; Hong Wang; Xiao-Feng Yang
Journal:  Front Biosci (Elite Ed)       Date:  2012-01-01

7.  Plasma miR-122 and miR-3149 Potentially Novel Biomarkers for Acute Coronary Syndrome.

Authors:  Xiangdong Li; Yuejin Yang; Laiyuan Wang; Shubin Qiao; Xiangfeng Lu; Yongjian Wu; Bo Xu; Hongfan Li; Dongfeng Gu
Journal:  PLoS One       Date:  2015-05-01       Impact factor: 3.240

8.  Signature of circulating microRNAs as potential biomarkers in vulnerable coronary artery disease.

Authors:  Jingyi Ren; Jing Zhang; Ning Xu; Guanping Han; Qiang Geng; Junxian Song; Sufang Li; Jianqing Zhao; Hong Chen
Journal:  PLoS One       Date:  2013-12-05       Impact factor: 3.240

9.  MiR-106b-5p Inhibits Tumor Necrosis Factor-α-induced Apoptosis by Targeting Phosphatase and Tensin Homolog Deleted on Chromosome 10 in Vascular Endothelial Cells.

Authors:  Jing Zhang; Su-Fang Li; Hong Chen; Jun-Xian Song
Journal:  Chin Med J (Engl)       Date:  2016-06-20       Impact factor: 2.628

10.  The potential inhibitory effects of miR‑19b on vulnerable plaque formation via the suppression of STAT3 transcriptional activity.

Authors:  Sufang Li; Qiang Geng; Hong Chen; Jing Zhang; Chengfu Cao; Feng Zhang; Junxian Song; Chuanfen Liu; Wenqing Liang
Journal:  Int J Mol Med       Date:  2017-11-17       Impact factor: 4.101

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.